Clinical trials: Refractory to Standard Therapies
Aplastic Anemia
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
This Phase II open-label interventional clinical trial aims to evaluate the efficacy of romiplostim, in patients with severe aplastic anemia (SAA), both treatment naïve and relapsed/refractory, in inducing trilineage…
- Trial name
- NCT07001254
- Testing
- Romiplostim, Immunosuppressive therapy (IST)
- Where
- United States
- Sponsor
- Anjali Sharathkumar
Multiple Myeloma
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as…
- Trial name
- NCT01421186
- Testing
- MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone
- Where
- 10 sites in Austria, Germany
- Volunteers
- 91 people
- Sponsor
- MorphoSys AG
Advanced Unresectable Solid Tumors
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
This is a first-in-human, open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable solid tumors…
- Trial name
- NCT02508441
- Testing
- Andes-1537 for Injection
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andes Biotechnologies
Metastatic Solid Tumors
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options.
- Trial name
- NCT00878423
- Testing
- AT13387
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Astex Pharmaceuticals, Inc.